The 50-patient study is evaluating ADX-PSA alone as a treatment for metastatic prostate cancer, and in combination with Keytruda, Merck's blockbuster anti-PD-1 cancer therapy.
The data for 37 patients taking part in the study showed a median overall survival rate of 21.1 months, which compares favorably to traditional therapies.
Broader stimulation of the immune system, including B-cell activation, was also observed when ADX-PSA was taken with Keytruda. The combination of ADXS-PSA and Keytruda was well tolerated by participating patients as well.
In response to these results, Advaxis shares climbed 16.4% to $6.86 in afternoon trade.
“Based on the prolonged survival data and strong safety profile to date, we believe that continued clinical development of ADXS-PSA in combination with Keytruda is warranted and represents a potentially significant opportunity for Advaxis,” said Kenneth Berlin, CEO of Advaxis, in a statement.
News of the promise of clinical findings for ADXS-PSA comes on the heels of preliminary data from a Phase 1 trial of ADX-NEO, another of the company’s cancer immunotherapies, showing “substantial” anti-tumor activity.
Data from both studies were presented at the American Association for Cancer Research’s annual meeting taking place this week in Atlanta, Georgia.
Contact Ellen Kelleher at email@example.com